Neuro-Bio Ltd

Neuro-Bio Ltd is a biotechnology company based in Abingdon, Oxfordshire, England, founded in 2013. The company specializes in developing diagnostic and therapeutic strategies for neurodegenerative diseases, with a strong focus on Alzheimer's disease. Neuro-Bio emerged from extensive research by Professor Baroness Greenfield at Oxford University and has made significant strides in understanding the mechanisms of neurodegeneration.

The company's core technology revolves around T14, a molecule identified as toxic in the adult brain, which plays a crucial role in neurodegeneration. Neuro-Bio is actively developing therapeutics targeting T14 for neuroprotection and creating diagnostic tests for early detection of Alzheimer's disease. Additionally, the company is working on advanced assets for drug delivery in fibrotic liver disease and personal care products, collaborating with major pharmaceutical companies and firms like Unilever. Neuro-Bio aims to leverage its partnerships and funding to enhance its research and development efforts.